Spruce Biosciences reports FY2022 net loss $46.2M, cash $79.1M; pipeline updates

SPRUCE BIOSCIENCES, INC.

Net loss $46.2M for FY2022 vs $42.3M in 2021; R&D expenses $35.2M, G&A $12.1M.
Cash, equivalents and investments $79.1M as of Dec 31, 2022; additional $53.6M private placement closed Feb 2023.
CAHmelia-203 in adult classic CAH surpassed 50% enrollment; topline data expected H2 2023.
Strategic partnership with Kaken Pharmaceutical for tildacerfont in Japan; $15M upfront received; cash runway into 1H 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SPRUCE BIOSCIENCES, INC. reported the year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021..

Period: the year ended December 31, 2022
Net income: Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021.
Result: reported results

Exact text from the filing

Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the full year ended December 31, 2022 and providing corporate updates.

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-008448

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.